Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-raltegravir
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-raltegravir is a radiopharmaceutical consisting of the HIV integrase inhibitor raltegravir labeled with radioactive fluorine-18. It is used as a PET imaging agent to study the distribution of raltegravir in the body, particularly in HIV-infected patients. This allows researchers to track how the drug distributes through tissues and potential HIV reservoirs, providing valuable information about antiretroviral drug penetration.
- Other names
- 5G8B507W3F1236352-56-9
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on 18F-raltegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-raltegravir.